Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011 and as of October 2014 Crucell is changing its identity into Janssen. For Janssen, the acquisition of Crucell has provided a firm foothold in the increasingly important field of disease prevention. Ultimately, this should mean that many more people around the world can live longer, healthier lives—and we are passionately committed to ma...
Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011 and as of October 2014 Crucell is changing its identity into Janssen. For Janssen, the acquisition of Crucell has provided a firm foothold in the increasingly important field of disease prevention. Ultimately, this should mean that many more people around the world can live longer, healthier lives—and we are passionately committed to making that happen.
Innovation is the driving force behind our strong vaccine research and development pipeline. We have promising candidates in preclinical and clinical development, supported by a range of patented technologies such as our PER.C6® human cell-line technology, which will enable faster and more cost-effective production of our future vaccines and biologicals.
Clean water, immunization, and antiviral and antibacterial medicines are considered the top three interventions driving improvements in public health. And with infectious diseases on the rise worldwide, developing innovative products to prevent or treat them is becoming increasingly urgent.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.